Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients

Pharmacogenomics

Volumn 12, Issue 9, 2011, Pages 1293-1303

  Santoro, Ana ^a   Felipe, Claudia R ^b   Tedesco Silva, Helio ^b   Medina Pestana, Jose O ^b   Struchiner, Claudio J ^c   Ojopi, Elida B ^d   Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ABCB1; Brazil; calcineurin inhibitors; cyclosporine; CYP3A5; renal transplant; tacrolimus

Indexed keywords

ADENINE; AZATHIOPRINE; CYCLOSPORIN A; GUANINE; METHYLPREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMINE;

ABCB1 GENE; ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BODY SURFACE; BRAZILIAN; CLINICAL FEATURE; CONTROLLED STUDY; CYP3A5 GENE; DEMOGRAPHY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE REDUCTION; ETHNIC GROUP; FEMALE; GENE; GENE INSERTION; GENETIC DISORDER; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HUMAN; HUMAN TISSUE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHARMACOGENOMICS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; BRAZIL; CALCINEURIN; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 80052923257     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.70     Document Type: Article

References (46)

1. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6, 267-276 (2005).
2. Haufroid V, Wallemacq P, van Kerckhove V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant. 6, 2760-2713 (2006).
3. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identifcation of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43, 630-635 (1988).
4. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20, 753-761 (1992).
5. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268, 6077-6080 (1993). (Pubitemid 23099291)
6. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88, S62-S67 (2009).
7. Wang J. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev. Mol. Diag. 9, 383-390 (2009).
8. Ware N, MacPhee IA. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr. Opin. Mol. Ther. 12, 270-283 (2010).
9. Burckart GJ, Amur S. Update on the clinical pharmacogenomics of organ transplantation. Pharmacogenomics 11, 227-236 (2010).
10. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 49, 141-175 (2010).
11. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
12. Haufroid V, Mourad M, van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004). (Pubitemid 38373108)
13. MacPhee IA, Fredericks S, Tai T et al. The infuence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4, 914-919 (2004). (Pubitemid 38745590)
14. Macphee IA, Fredericks S, Mohamed M et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79, 499-502 (2005). (Pubitemid 40280186)
15. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A. Signifcant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant. Proc. 40, 1690-1695 (2008). (Pubitemid 351853194)
16. Press RR, Ploeger BA, den Hartigh J et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther. Drug Monit. 31, 187-197 (2009).
17. Suarez-Kurtz G, Pena SDJ. Pharmacogenetic Studies in the Brazilian population. In: Pharmacogenomics in Admixed Pop ulations. Suarez-Kurtz G (Ed.). Landes Biosciences, TX, USA, 75-98 (2007).
18. Suarez-Kurtz G. The implications of population admixture in race-based drug prescription. Clin. Pharmacol. Ther. 83, 399-400 (2008). (Pubitemid 351272632)
19. Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front. Pharmacol. 1, 118 (2010).
20. Lee SJ, Usmani KA, Chanas B et al. Genetic fndings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13, 461-472 (2003). (Pubitemid 37034588)
21. Wojnowski L, Turner PC, Pedersen B et al. Increased levels of afatoxin-albumin adducts are associated with CYP3A5 polymorphisms in the Gambia, West Africa. Pharmacogenetics 14, 691-700 (2004). (Pubitemid 39411269)
22. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med. Genet. 6, 19 (2005).
23. Mirghani RA, Sayi J, Aklillu E et al. CYP3A5 genotype has signifcant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet. Genomics 16, 637-645 (2006). (Pubitemid 44223075)
24. Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 225, 275-282 (2005). (Pubitemid 40835875)
25. Ferreira PE, Veiga MI, Cavaco I et al. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther. Drug Monit. 30, 10-15 (2008). (Pubitemid 351161093)
26. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism ana lysis in myeloid leukemia. Oncol. Rep. 9, 327-329 (2002).
27. Lee S-J, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6(4), 357-371 (2005). (Pubitemid 40916359)
28. Estrela RC, Ribeiro FS, Carvalho RS et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9, 267-276 (2008). (Pubitemid 351803932)
29. 2 statistic for fxed effects in the linear mixed model. Stat. Med. 27, 6137-6157 (2008).
30. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. 1st Edition. Springer-Verlag, NY, USA (2000).
31. R Development Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Áustria (2009).
32. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8, 1299-1306 (2007). (Pubitemid 350162846)
33. Estrela RC, Santoro AB, Barroso PF, Tuyama M, Suarez-Kurtz G. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin. Pharmacol. Ther. 84, 205-207 (2008).
34. MacPhee IA, Holt DW. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 85, 163-165 (2008). (Pubitemid 351156844)
35. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010).
36. Wang P, Mao Y, Razo J et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 11(10), 1389-1402 (2010).
37. Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003). (Pubitemid 37083100)
38. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifes the risk of the acute allograft rejection in renal transplant recipients. Transplantation 86, 1206-1213 (2008).
39. Wang Y, Wang C, Li J et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur. J. Clin. Pharmacol. 65, 239-247 (2009).
40. Press RR, Ploeger BA, den Hartigh J et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur. J. Clin. Pharmacol. 66(6), 579-590 (2010).
41. Wu KH, Cui YM, Guo JF et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab. Dispos. 33, 1268-1275 (2005).
42. Sun B, Li XY, Gao JW et al. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. Ther. Drug Monit. 32, 715-722 (2010).
43. Anglicheau D, Flamant M, Schlageter MH et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol. Dial. Transplant. 18(11), 2409-2414 (2003). (Pubitemid 37336834)
44. Hesselink DA, Ngyuen H, Wabbijn M et al. Tacrolimus dose requirement in renal transplant recipients is signifcantly higher when used in combination with corticosteroids. Br. J. Clin. Pharmacol. 56(3), 327-330 (2003). (Pubitemid 37059661)
45. Hesselink DA, van Schaik RH, van Agteren M et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet. Genomics 18(4), 339-348 (2008). (Pubitemid 351367527)
46. Quteineh L, Verstuyft C, Furlan V et al. Infuence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6), 546-552 (2008).